Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis

被引：0
|
作者：
Li, L. [1 ]
Zhang, D. [1 ]
Wu, Y. [1 ]
Ma, F. [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Med Oncol, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.623
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
447P
引用
收藏
页码：S369 / S369
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
    Li, Lixi
    Zhang, Di
    Wu, Yun
    Wang, Jiayu
    Ma, Fei
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (06):
  • [2] Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis
    Yu, Yushuai
    Huang, Kaiyan
    Lin, Yuxiang
    Zhang, Jie
    Song, Chuangui
    [J]. CANCER MEDICINE, 2023, 12 (14): : 15090 - 15100
  • [3] Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
    Shanshan Chen
    Yu Liang
    Zhangying Feng
    Mingxia Wang
    [J]. BMC Cancer, 19
  • [4] Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
    Chen, Shanshan
    Liang, Yu
    Feng, Zhangying
    Wang, Mingxia
    [J]. BMC CANCER, 2019, 19 (01)
  • [5] Efficacy of tyrosine kinase inhibitors (TKI) in the treatment of patients with HER2-positive (HER2+) breast cancer with or without brain metastases: A systematic review and meta-analysis
    Nader-Marta, Guilherme
    Martins-Branco, Diogo
    Agostinetto, Elisa
    Bruzzone, Marco
    Ceppi, Marcello
    Lambertini, Matteo
    Kotecki, Nuria
    Awada, Ahmad
    de Azambuja, Evandro
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [6] Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis
    Nader-Marta, G.
    Martins-Branco, D.
    Agostinetto, E.
    Bruzzone, M.
    Ceppi, M.
    Danielli, L.
    Lambertini, M.
    Kotecki, N.
    Awada, A.
    de Azambuja, E.
    [J]. ESMO OPEN, 2022, 7 (03)
  • [7] Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis
    Chen, Xuan
    Li, Yuqing
    Lin, Mingfei
    Lu, Yufu
    [J]. MEDICINE, 2023, 102 (22) : E33925
  • [8] Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis
    Michelon, I. F.
    Vilbert, M. Silveira
    Marinho, A. D.
    Castro, C. E. D. R.
    Dacoregio, M. I.
    Stecca, C.
    Soares, L. R.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S357 - S357
  • [9] Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
    Wilson, Florence R.
    Coombes, Megan E.
    Brezden-Masley, Christine
    Yurchenko, Mariya
    Wylie, Quinlan
    Douma, Reuben
    Varu, Abhishek
    Hutton, Brian
    Skidmore, Becky
    Cameron, Chris
    [J]. SYSTEMATIC REVIEWS, 2018, 7
  • [10] Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies
    Martin, Antony P.
    Downing, Jennifer
    Cochrane, Madeleine
    Collins, Brendan
    Francis, Ben
    Haycox, Alan
    Alfirevic, Ana
    Pirmohamed, Munir
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 130 : 92 - 107
12345